Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:QLGN NASDAQ:SPRB NASDAQ:TNFA NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeQLGNQualigen Therapeutics$2.17-1.4%$3.42$2.00▼$12.11$3.60M-0.172.57 million shs33,591 shsSPRBSpruce Biosciences$0.11-0.9%$0.08$0.06▼$0.61$4.60M2.4815,528 shs31,531 shsTNFATNF Pharmaceuticals$0.10-7.4%$0.14$0.08▼$2.16$1.55M1.8273.67 million shs45.54 million shsVIVSVivoSim Labs$1.85-1.1%$1.77$1.41▼$21.96$4.86M0.9486,026 shs33,542 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceQLGNQualigen Therapeutics-1.36%-22.50%-33.44%-39.55%-80.48%SPRBSpruce Biosciences-0.91%-7.16%+49.52%+47.50%-78.92%TNFATNF Pharmaceuticals-7.42%-13.53%-12.78%-49.80%+10,099,900.00%VIVSVivoSim Labs-1.07%-17.04%+20.92%+184,999,900.00%+184,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASPRBSpruce Biosciences3.0295 of 5 stars3.05.00.00.02.01.71.3TNFATNF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceQLGNQualigen Therapeutics 0.00N/AN/AN/ASPRBSpruce Biosciences 2.00Hold$1.751,505.50% UpsideTNFATNF Pharmaceuticals 0.00N/AN/AN/AVIVSVivoSim Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookQLGNQualigen Therapeutics$4.98M0.71N/AN/A($4.12) per share-0.53SPRBSpruce Biosciences$4.91M0.94N/AN/A$1.88 per share0.06TNFATNF PharmaceuticalsN/AN/AN/AN/A$2.87 per shareN/AVIVSVivoSim Labs$140K34.36N/AN/A$5.54 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateQLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-260.91%8/16/2025 (Estimated)SPRBSpruce Biosciences-$47.92M-$1.32N/AN/AN/A-555.23%-62.10%-47.49%8/11/2025 (Estimated)TNFATNF Pharmaceuticals-$23.36M-$6.67N/A∞N/AN/A-97.38%-37.37%8/18/2025 (Estimated)VIVSVivoSim Labs-$2.48M-$10.20N/A∞N/A-1,725.00%-46.87%-28.62%N/ALatest TNFA, QLGN, SPRB, and VIVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SPRBSpruce Biosciences-$0.25N/AN/AN/A$0.67 millionN/A7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/A5/15/2025Q1 2025TNFATNF PharmaceuticalsN/A-$0.36N/A-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioQLGNQualigen TherapeuticsN/A1.011.01SPRBSpruce Biosciences0.015.365.36TNFATNF PharmaceuticalsN/A1.371.37VIVSVivoSim LabsN/A3.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipQLGNQualigen Therapeutics3.18%SPRBSpruce Biosciences91.71%TNFATNF Pharmaceuticals9.64%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipQLGNQualigen Therapeutics1.80%SPRBSpruce Biosciences6.90%TNFATNF Pharmaceuticals0.45%VIVSVivoSim Labs3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableQLGNQualigen Therapeutics501.64 million1.61 millionNot OptionableSPRBSpruce Biosciences2042.23 million37.54 millionOptionableTNFATNF Pharmaceuticals614.18 million14.12 millionN/AVIVSVivoSim Labs202.60 million2.50 millionN/ATNFA, QLGN, SPRB, and VIVS HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNFA, QLGN, SPRB, and VIVS Company DescriptionsQualigen Therapeutics NASDAQ:QLGN$2.17 -0.03 (-1.36%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.17 +0.00 (+0.23%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Spruce Biosciences NASDAQ:SPRB$0.11 0.00 (-0.91%) As of 08/1/2025 03:36 PM EasternSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.TNF Pharmaceuticals NASDAQ:TNFA$0.10 -0.01 (-7.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.10 +0.00 (+3.96%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.VivoSim Labs NASDAQ:VIVS$1.85 -0.02 (-1.07%) As of 08/1/2025 03:59 PM EasternOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
